Novel Treatment Receives FDA RMAT Designation in R/R Mantle Cell Lymphoma
The anti-CD19/4-1BB CAR T-cell therapy candidate elicited an ORR and CR rate of 100% each in patients with relapsed/refractory MCL.
Previous Post
Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug
Next Post
Addressing the Limitations of Current ITP Therapies
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago